Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,011) <sup>3</sup>	%	N (total = 279) <sup>3</sup>	%	N (total = 221) <sup>3</sup>	%
Breast Cancer Subtype for 1st Diagnosis						
Invasive <sup>4</sup>	2,268	75.3	197	70.6	171	77.4
Ductal only (no lobular component) <sup>5</sup>	1,630	54.1	128	45.9	121	54.8
Lobular only (no ductal component) <sup>5</sup>	212	7.0	9	3.2	11	5.0
Ductal and lobular <sup>5,6</sup>	156	5.2	7	2.5	11	5.0
Inflammatory	5	0.2	1	0.4	0	0.0
Paget's	8	0.3	2	0.7	0	0.0
Phyllodes <sup>7</sup>	5	0.2	0	0.0	0	0.0
Other/unknown if ductal or lobular8	252	8.4	50	17.9	28	12.7
In situ	725	24.1	78	28.0	48	21.7
Ductal only (no lobular component)9	600	19.9	69	24.7	42	19.0
Lobular only (no ductal component) <sup>9</sup>	96	3.2	6	2.2	6	2.7
Ductal and lobular <sup>6,9</sup>	16	0.5	0	0.0	0	0.0
Paget's	5	0.2	0	0.0	0	0.0
Other/unknown if ductal or lobular	8	0.3	3	1.1	0	0.0
Invasiveness unknown <sup>10</sup>	18	0.6	4	1.4	2	0.9
Stage at 1st Breast Cancer Diagnosis						
0	650	23.9	64	28.8	43	22.6
1	1367	50.2	90	40.5	91	47.9
II	518	19.0	51	23.0	37	19.5
III	132	4.8	13	5.9	16	8.4
IV	19	0.7	1	0.5	1	0.5
Unknown, missing, cannot stage	287		57		31	
Estrogen Receptor (ER) Status for 1st Breast	Cancer Diagnosis					
Positive	2,207	85.3	159	77.2	143	81.7
Negative	378	14.6	45	21.8	32	18.3
Borderline	3	0.1	2	1.0	0	0.0
Unknown, missing, not performed	423		73		46	
Progesterone Receptor (PR) Status for 1st Br	east Cancer Diagnos	is				
Positive	1,823	73.1	119	59.8	113	66.5
Negative	664	26.6	79	39.7	57	33.5
Borderline	6	0.2	1	0.5	0	0.0
Unknown, missing, not performed	518		80		51	
HER2 Amplification Status for 1st Breast Can	cer Diagnosis					
Positive	269	12.6	24	15.0	27	17.9
Negative	1,830	85.8	135	84.4	123	81.5
Borderline	35	1.6	1	0.6	1	0.7
Unknown, missing, not performed	877		119		70	

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,011) <sup>3</sup>	%	N (total = 279) <sup>3</sup>	%	N (total = 221) <sup>3</sup>	%
Combined ER, PR, HER2 Status						
Triple negative (ER-, Pr-, and HER2-)	199	7.9	33	16.3	18	10.7
Not triple negative	2,309	92.1	169	83.7	151	89.3
Unknown, missing, not performed	503		77		52	
Age (in years) at Breast Cancer Diagnos	sis 11					
Under 50	326	10.8	46	16.5	35	15.8
50-64	1431	47.5	142	50.9	122	55.2
65 and older	1254	41.6	91	32.6	64	29.0
Menopausal Status at Breast Cancer Di	agnosis					
Pre-menopausal	519	17.3	56	20.2	54	24.4
Post-menopausal	2,484	82.7	221	79.8	167	75.6
Unknown	8		2		0	

Abbreviations: BrCa= Breast cancer; DCIS=Ductal carcinoma *in situ*; LCIS = Lobular carcinoma *in situ*; MR = Medical report (medical record and/or pathology report)

- <sup>1</sup> Breast cancer events (any type) are defined by the following ICD10 codes: D05 (includes lobular carcinoma in situ, ductal carcinoma in situ, other and unspecified *in situ* breast carcinomas), C50 (all invasive breast cancer), and D48.6 (neoplasm of uncertain behavior of breast)
- <sup>2</sup> Data release 7.0 includes events from follow-up phases that closed **on or before 9/15/2017**, excluding all data from participants who have withdrawn their data from the study (n=2). To be considered a breast cancer event, breast must be the primary site, and the cancer diagnosis must have occurred after the participant's baseline date. Consequently, Data Release 7.0 breast cancer events (any type) exclude a) through c) below:
  - a) Breast cancers diagnosed prior to participant's baseline date;
  - b) Breast cancers diagnosed with unknown timing relative to baseline;
  - c) Unknown primary cancer diagnoses where breast was unlikely to be the primary site, but the possibility could not be ruled out
- <sup>3</sup> Confirmed by medical report (medical record or pathology report)
- <sup>4</sup> Includes 'presumed invasive' (i.e. a carcinoma in situ with positive nodes)
- Ductal only, Lobular only, and Ductal and Lobular exclude inflammatory breast cancer and Paget's
- <sup>6</sup> Includes BrCa events with a) tumors with mixed ductal and lobular characteristics and/or b) multiple tumors of different histology (e.g. a ductal only tumor and a lobular only tumor)
- <sup>7</sup> Phyllodes is neither ductal nor lobular; it is a sarcoma
- 8 Includes: a) Invasive but unknown if ductal or lobular; b) Invasive type "neither ductal nor lobular, not otherwise specified"; and c) Presumed invasive in situ tumor, positive nodes; these are typically self-report without MR confirmation
- <sup>9</sup> Ductal only, Lobular only, and Ductal and Lobular exclude Paget's
- <sup>10</sup> Invasiveness unknown includes: a) Unknown if invasive or *in situ* and unknown if ductal or lobular; b) Ductal but unknown if invasive or *in situ*; c) Neither ductal nor lobular (other) but not otherwise specified and unknown if invasive or *in situ*; d) Per MR, unable to determine if DCIS or atypical ductal hyperplasia; and e) Per MR, unable to determine if LCIS or atypical lobular hyperplasia
- <sup>11</sup> For those missing age at diagnosis, age was imputed as the midpoint of the range of plausible ages at diagnosis